Protara Therapeutics, Inc. (TARA)

Market Cap	15.91M
Revenue (ttm)	n/a
Net Income (ttm)	-69.17M
Shares Out	11.36M
EPS (ttm)	-6.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,564
Open	1.45
Previous Close	1.40
Day's Range	1.38 - 1.47
52-Week Range	1.04 - 4.18
Beta	1.62
Analysts	Strong Buy
Price Target	22.50 (+1,507.14%)
Earnings Date	Nov 3, 2023

About TARA

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Jesse Shefferman
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: TARA

Analyst Forecast

According to 2 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price forecast is $22.5, which is an increase of 1,507.14% from the latest price.

Price Target

$22.5

(1,507.14% upside)

Analyst Consensus: Strong Buy